Results 61 to 70 of about 82,941 (302)

Development of nanocomplex mimic‐hsa‐miR‐143‐3p loaded exosome (exo‐miR) to inhibit viability, migration and proliferation of triple‐negative breast cancer

Indonesian Journal of Biotechnology
Breast cancer represents the highest number of cancer cases in Indonesia, with triple‐negative breast cancer (TNBC) being a common subtype (10–15%). MicroRNAs play a role in cancer epigenetics and contributing as core factors to the disease.
Fita Nilasari, Sofia Mubarika Haryana, Dwi Aris Agung Nugrahaningsih, Pamungkas Bagus Satriyo   +3 more
doaj   +1 more source

Multimodal Actuation and Environment Adaptive Strategies of Bio‐Inspired Micro/Nanorobots in Precision Medicine

Advanced Robotics Research, EarlyView.
An introduction for multidrive and environment‐adaptive micro/nanorobotics: design and fabrication strategies, intelligent actuation, and their applications. Various intelligent actuation approaches—magnetic, acoustic, optical, chemical, and biological—can be synergistically designed to enhance flexibility and adaptive behavior for precision medicine ...
Aiqing Ma, Han Gong, Jiacheng Ouyang, Liqi Chen, Tianfang Kang, Yiran He, Guojun Huang, Sidi Zheng, Ting Yin, Hong Pan, Lintao Cai   +10 more
wiley   +1 more source

Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression

eLife, 2021
Mortality from triple negative breast cancer (TNBC) is significantly higher in African American (AA) women compared to White American (WA) women emphasizing ethnicity as a major risk factor; however, the molecular determinants that drive aggressive ...
Sumit Siddharth, Sheetal Parida, Nethaji Muniraj, Shawn Hercules, David Lim, Arumugam Nagalingam, Chenguang Wang, Balazs Gyorffy, Juliet M Daniel, Dipali Sharma   +9 more
doaj   +1 more source

RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. [PDF]

, 2019
Tumor subtype-specific metabolic reprogrammers could serve as targets of therapeutic intervention. Here we show that triple-negative breast cancer (TNBC) exhibits a hyper-activated cholesterol-biosynthesis program that is strongly linked to nuclear ...
Bold, Richard J, Borowsky, Alexander D, Cai, Demin, Chen, Hong-Wu, Chen, Xinbin, Evans, Ronald M, Fiehn, Oliver, Gao, Bei, Huang, Zenghong, Jiang, Yuqian, Kung, Hsing-Jien, Lam, Kit S, Lara, Primo N, Li, Jian Jian, Li, Jin, To, Ka-Fai, Wang, Junjian, Wu, Feng, Xu, Jianzhen, Zhao, Ruqian, Zou, Hongye, Zou, June X   +21 more
core  

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. [PDF]

, 2019
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk.
Aalfs, Cora M, ABCTB Investigators, Adank, Muriel A, Adlard, Julian, Agata, Simona, Agnarsson, Bjarni A, Ahearn, Thomas, Aittomäki, Kristiina, Ambrosone, Christine B, Andrews, Lesley, Anton-Culver, Hoda, Antonenkova, Natalia N, Arndt, Volker, Arnold, Norbert, Aronson, Kristan J, Arun, Banu K, Asseryanis, Ella, Auber, Bernd, Auvinen, Päivi, Azzollini, Jacopo, Balmaña, Judith, Barkardottir, Rosa B, Barnes, Daniel R, Barrowdale, Daniel, Barwell, Julian, Beane Freeman, Laura E, Beauparlant, Charles Joly, Beckmann, Matthias W, Behrens, Sabine, Benitez, Javier, Berger, Raanan, Bermisheva, Marina, Blanco, Amie M, Blomqvist, Carl, Bogdanova, Natalia V, Bogliolo, Massimo, Bojesen, Anders, Bojesen, Stig E, Bolla, Manjeet K, Bonanni, Bernardo, Borg, Ake, Brady, Angela F, Brauch, Hiltrud, Brenner, Hermann, Brüning, Thomas, Burwinkel, Barbara, Buys, Saundra S, Cadoo, Karen, Caldés, Trinidad, Caleca, Laura, Caliebe, Almuth, Caligo, Maria A, Campa, Daniele, Campbell, Ian G, Canzian, Federico, Castelao, Jose E, Catucci, Irene, Chang-Claude, Jenny, Chanock, Stephen J, Claes, Kathleen BM, Clarke, Christine L, Collavoli, Anita, Conner, Thomas A, Cox, David G, Cybulski, Cezary, Czene, Kamila, Daly, Mary B, de la Hoya, Miguel, Dennis, Joe, Devilee, Peter, Diez, Orland, Ding, Yuan Chun, Dite, Gillian S, Ditsch, Nina, Domchek, Susan M, Dorfling, Cecilia M, Dos-Santos-Silva, Isabel, Durda, Katarzyna, Dwek, Miriam, Eccles, Diana M, Ekici, Arif B, Eliassen, A Heather, Ellberg, Carolina, Eriksson, Mikael, Evans, D Gareth, Fasching, Peter A, Figlioli, Gisella, Figueroa, Jonine, Flyger, Henrik, Foulkes, William D, Friebel, Tara M, Friedman, Eitan, Gabrielson, Marike, Gaddam, Pragna, Kiiski, Johanna I, Lasheras, Sandra Viz, Leslie, Goska, Michailidou, Kyriaki, Muranen, Taru A, Pujol, Roser   +99 more
core  

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

Advanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source

CPEB2 Affects Malignant Progression of Triple-Negative Breast Cancer Through MEK/ERK Signaling Pathway

Zhongliu Fangzhi Yanjiu
ObjectiveTo investigate the expression of CPEB2 in triple-negative breast cancer (TNBC) and its impact on the malignant progression of tumors. MethodsThe expression level of CPEB2 in breast cancer was analyzed through a database, and the differential ...
Munire·ABULA, Yuxiang LI, Tao WU
doaj   +1 more source

Real-World Efficacy and Safety of the KEYNOTE-522 Protocol for Neoadjuvant Triple-Negative Breast Cancer: A Single-Center Experience. [PDF]

Batna Journal of Medical Sciences
Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, is an aggressive subtype associated with a high risk of relapse and ...
Assia BENSALEM, Khouloud BRAHIMI, Abdelaziz AMMARI, Sihem BENSALEM, Nour Djihane BOUATROUS, Meryem BOUDJERDA   +5 more
doaj   +1 more source

Synthesis of Curcumin Derivatives and Analysis of Their Antitumor Effects in Triple Negative Breast Cancer (TNBC) Cell Lines [PDF]

, 2019
We analyzed antitumor effects of a series of curcumin analogues. Some of them were obtained by reaction of substitution involving the two phenolic OH groups of curcumin while the analogues with a substituent at C-4 was prepared following an original ...
Barattucci A, Bonaccorsi PM, Labbozzetta M, Notarbartolo M, Poma P, Salerno TMG   +5 more
core   +1 more source